Harvard Pulmonary and Critical Care Medicine 2023

OVERVIEW

This comprehensive course provides education and updates to optimize your care of patients with:

• Post-acute sequelae of COVID-19
• Chronic cough
• COPD
• Asthma
• Lung nodules
• Lung cancer
• Sleep-disordered breathing
• GERD
• Sepsis
• ARDS
• Sarcoidosis
• IPF
• Pleural disease
• Pneumonia
• Tuberculosis
• Surgical emergencies
• Thromboembolism
• Lung transplantation
• Neurologic issues in the ICU
• Septic shock
• Interstitial lung disease
• Bronchiectasis
• Cystic fibrosis
• Atypical mycobacterial disease
• Pulmonary hypertension
• Cardiopulmonary disorders
• Complications from cardiac arrest
• Hypersensitivity pneumonitis
• Occupational and environmental lung disease
• Acute respiratory failure
• Vaping-related lung disease
• Hemorrhage and ANCA-associated disease

REASONS TO ATTEND IN 2023

All sessions are led by master clinicians who deliver information in inspiring and entertaining ways, and provide specific recommendations to incorporate the latest updates into your practice. Education covers:

• COVID-19, PASC, and emerging diseases
• Advanced techniques in interventional pulmonology
• High-flow oxygen therapy for respiratory failure
• New biologics for asthma
• Lung microbiome: emerging implications for lung health
• Emerging evidence for targeted temperature management
• Evaluating occupational and environmental lung disease
• Prescribing medications for interstitial lung disease
• Pulmonary embolus: the latest treatment strategies
• State-of-the-art management of the critically ill patient
• Guidance to conduct end-of-life discussions
• Updates in pulmonary pathology
• New treatment options in cystic fibrosis
• Handling neurologic and surgical emergencies in the medical ICU
• The state of the art in interventional bronchoscopy
• The most current guidelines for treating sepsis
• Evidence-based treatment of ARDS
• Updates on vaping-related lung disease
• New therapeutics in the age of immunology
• Guidance to navigate controversies surrounding therapeutic hypothermia and post-cardiac arrest prognosis
• New approaches that improve outcomes for patients with unexplained chronic cough
• Current guidelines for management of pulmonary nodules
• Targeted therapies and immunotherapies for lung cancer
• When to consider lung transplantation and eligibility
• When and how to use the newest drugs in IPF
• Expert advice on atypical mycobacterial diagnostics and therapy
• New concepts in the use of vasopressors in septic shock
• New drugs and combinations in pulmonary hypertension
• New evidence on sedation, analgesia, and early mobility
• Point-of-care pulmonary ultrasound in the intensive care unit